BeiGene, Ltd. (NASDAQ:BGNE) Insider Titus B. Ball Sells 137 Shares

BeiGene, Ltd. (NASDAQ:BGNE) insider Titus B. Ball sold 137 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $189.94, for a total value of $26,021.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

BeiGene Trading Up 1.6 %

NASDAQ:BGNE opened at $191.58 on Friday. The firm has a market capitalization of $18.56 billion, a P/E ratio of -25.31 and a beta of 0.59. The business has a 50 day simple moving average of $169.96 and a 200 day simple moving average of $161.41. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.98 and a quick ratio of 1.75. BeiGene, Ltd. has a 12-month low of $126.97 and a 12-month high of $213.83.

BeiGene (NASDAQ:BGNE) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($1.15) earnings per share for the quarter, beating the consensus estimate of ($2.27) by $1.12. The firm had revenue of $929.20 million for the quarter, compared to the consensus estimate of $810.34 million. BeiGene had a negative net margin of 16.91% and a negative return on equity of 14.93%. BeiGene’s quarterly revenue was up 56.1% compared to the same quarter last year. During the same period last year, the firm posted ($3.64) EPS. Equities research analysts predict that BeiGene, Ltd. will post -5.13 EPS for the current year.

Hedge Funds Weigh In On BeiGene

Institutional investors and hedge funds have recently bought and sold shares of the stock. Capital International Investors boosted its stake in BeiGene by 11.5% during the 1st quarter. Capital International Investors now owns 7,064,428 shares of the company’s stock valued at $1,104,806,000 after purchasing an additional 727,556 shares in the last quarter. Point72 Asset Management L.P. bought a new position in BeiGene during the second quarter valued at about $54,412,000. First Trust Advisors LP acquired a new position in BeiGene during the fourth quarter worth about $39,632,000. M&G Plc bought a new stake in BeiGene in the first quarter worth about $29,649,000. Finally, Goldman Sachs Group Inc. lifted its holdings in BeiGene by 175.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 214,339 shares of the company’s stock valued at $38,658,000 after acquiring an additional 136,458 shares during the last quarter. Institutional investors own 48.55% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Citigroup boosted their price objective on shares of BeiGene from $269.00 to $288.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. JPMorgan Chase & Co. increased their price target on BeiGene from $194.00 to $200.00 and gave the company an “overweight” rating in a report on Tuesday, August 20th. TD Cowen raised their price objective on BeiGene from $236.00 to $254.00 and gave the company a “buy” rating in a research note on Thursday, May 9th. Finally, Bank of America cut their target price on BeiGene from $180.00 to $152.50 and set a “neutral” rating on the stock in a research report on Tuesday, July 9th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $239.81.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.